LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 10 von insgesamt 95

Suchoptionen

  1. Artikel ; Online: New Real-World Insights Into Severe Asthma: All About the Eosinophil?

    Kurukulaaratchy, Ramesh J / Mistry, Heena

    Chest

    2021  Band 160, Heft 3, Seite(n) 789–790

    Mesh-Begriff(e) Anti-Asthmatic Agents/therapeutic use ; Asthma/drug therapy ; Eosinophils ; Humans ; Leukocyte Count
    Chemische Substanzen Anti-Asthmatic Agents
    Sprache Englisch
    Erscheinungsdatum 2021-09-06
    Erscheinungsland United States
    Dokumenttyp Editorial ; Comment
    ZDB-ID 1032552-9
    ISSN 1931-3543 ; 0012-3692
    ISSN (online) 1931-3543
    ISSN 0012-3692
    DOI 10.1016/j.chest.2021.05.030
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Dual biologic therapy for the treatment of rheumatic diseases and asthma: a case series.

    Malik, Mariam / Jones, Bryony / Williams, Emma / Kurukulaaratchy, Ramesh / Holroyd, Chris / Mason, Alice

    Rheumatology advances in practice

    2023  Band 7, Heft 1, Seite(n) rkad018

    Abstract: Objective: Combination biological therapies are being considered increasingly for patients with multiple co-morbidities requiring biologics. There are limited data available on this approach, and concerns remain about the possible risk of adverse events, ...

    Abstract Objective: Combination biological therapies are being considered increasingly for patients with multiple co-morbidities requiring biologics. There are limited data available on this approach, and concerns remain about the possible risk of adverse events, particularly infection.
    Methods: We present three patients on dual biologics for rheumatic disease and asthma. The biologic combinations used were etanercept and mepolizumab, infliximab and omalizumab, and etanercept and omalizumab. The time on combination biologic therapies ranged from 24 to 36 months. Patients were monitored for any serious adverse events.
    Results: All three patients were able to tolerate combined biologic therapies, with no serious adverse events. All three patients gained improvement in their rheumatic and asthma disease control, with reduction in disease activity scores and reduction in steroid usage.
    Conclusion: The decision to start dual biologic therapy should be considered carefully, on a case-by-case basis. The number of patients who are on combination biological therapy is small, and data are sparse. Real-world data are needed to examine the long-term benefits and risks of different forms of combination biologic therapies.
    Sprache Englisch
    Erscheinungsdatum 2023-02-03
    Erscheinungsland England
    Dokumenttyp Journal Article
    ISSN 2514-1775
    ISSN (online) 2514-1775
    DOI 10.1093/rap/rkad018
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Effects of air purifiers on rhinitis quality of life and perception of sleep quality in people with asthma: Randomised controlled trial.

    Kadalayil, Latha / Lowther, Scott / Fong, Wei Chern Gavin / Nicolas, Frédéric / Potter, Stephen / Larsson, Maria / Kurukulaaratchy, Ramesh / Arshad, Syed Hasan

    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

    2024  Band 54, Heft 5, Seite(n) 350–352

    Mesh-Begriff(e) Humans ; Quality of Life ; Asthma ; Female ; Male ; Rhinitis ; Sleep Quality ; Adult ; Air Filters ; Middle Aged ; Perception
    Sprache Englisch
    Erscheinungsdatum 2024-02-05
    Erscheinungsland England
    Dokumenttyp Letter ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 645204-8
    ISSN 1365-2222 ; 0954-7894 ; 0960-2178
    ISSN (online) 1365-2222
    ISSN 0954-7894 ; 0960-2178
    DOI 10.1111/cea.14459
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel: Recent Insights into the Management of Inflammation in Asthma.

    Rupani, Hitasha / Fong, Wei Chern Gavin / Kyyaly, Aref / Kurukulaaratchy, Ramesh J

    Journal of inflammation research

    2021  Band 14, Seite(n) 4371–4397

    Abstract: The present prevailing inflammatory paradigm in asthma is of T2-high inflammation orchestrated by key inflammatory cells like Type 2 helper lymphocytes, innate lymphoid cells group 2 and associated cytokines. Eosinophils are key components of this T2 ... ...

    Abstract The present prevailing inflammatory paradigm in asthma is of T2-high inflammation orchestrated by key inflammatory cells like Type 2 helper lymphocytes, innate lymphoid cells group 2 and associated cytokines. Eosinophils are key components of this T2 inflammatory pathway and have become key therapeutic targets. Real-world evidence on the predominant T2-high nature of severe asthma is emerging. Various inflammatory biomarkers have been adopted in clinical practice to aid asthma characterization including airway measures such as bronchoscopic biopsy and lavage, induced sputum analysis, and fractional exhaled nitric oxide. Blood measures like eosinophil counts have also gained widespread usage and multicomponent algorithms combining different parameters are now appearing. There is also growing interest in potential future biomarkers including exhaled volatile organic compounds, micro RNAs and urinary biomarkers. Additionally, there is a growing realisation that asthma is a heterogeneous state with numerous phenotypes and associated treatable traits. These may show particular inflammatory patterns and merit-specific management approaches that could improve asthma patient outcomes. Inhaled corticosteroids (ICS) remain the mainstay of asthma management but their use earlier in the course of disease is being advocated. Recent evidence suggests potential roles for ICS in combination with long-acting beta-agonists (LABA) for as needed use in mild asthma whilst maintenance and reliever therapy regimes have gained widespread acceptance. Other anti-inflammatory strategies including ultra-fine particle ICS, leukotriene receptor antagonists and macrolide antibiotics may show efficacy in particular phenotypes too. Monoclonal antibody biologic therapies have recently entered clinical practice with significant impacts on asthma outcomes. Understanding of the efficacy and use of those agents is becoming clearer with a growing body of real-world evidence as is their potential applicability to other treatable comorbid traits. In conclusion, the evolving understanding of T2 driven inflammation alongside a treatable traits disease model is enhancing therapeutic approaches to address inflammation in asthma.
    Sprache Englisch
    Erscheinungsdatum 2021-09-02
    Erscheinungsland New Zealand
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2494878-0
    ISSN 1178-7031
    ISSN 1178-7031
    DOI 10.2147/JIR.S295038
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel: A Role for Mucolytics and Expectorants in Aiding Inhaled Therapies in Asthma? [Response To Letter].

    Kurukulaaratchy, Ramesh J / Rupani, Hitasha / Fong, Wei Chern Gavin / Kyyaly, Aref

    Journal of inflammation research

    2021  Band 14, Seite(n) 5183–5185

    Sprache Englisch
    Erscheinungsdatum 2021-10-08
    Erscheinungsland New Zealand
    Dokumenttyp Journal Article ; Comment
    ZDB-ID 2494878-0
    ISSN 1178-7031
    ISSN 1178-7031
    DOI 10.2147/JIR.S341547
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel ; Online: Clinical features and later prognosis of replicable early-life wheeze clusters from two birth cohorts 12 years apart.

    Ngo, Suzanne Y / Venter, Carina / Anderson, William C / Picket, Kaci / Zhang, Hongmei / Arshad, S Hasan / Kurukulaaratchy, Ramesh J

    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology

    2023  Band 34, Heft 7, Seite(n) e13999

    Abstract: Background: Clustering techniques can define the heterogeneity of asthma and wheezing. Defining early-life wheezing clusters and associated asthma risk could potentially inform patient management strategies. Clustering models that yield replicable ... ...

    Abstract Background: Clustering techniques can define the heterogeneity of asthma and wheezing. Defining early-life wheezing clusters and associated asthma risk could potentially inform patient management strategies. Clustering models that yield replicable cluster groups will have greater validity and clinical utility. This study sought to identify early-life wheezing clusters that are translatable into clinical practice and assess their stability over time in two whole-population birth cohorts established a decade apart from the same geographical location.
    Methods: Nonparametric K-means cluster analysis was performed separately on two birth cohorts from the Isle of Wight, UK; the Isle of Wight Birth Cohort (IOWBC) and Food Allergy and Intolerance Research Cohort (FAIR), using clinically defining variables in wheezing subjects in the first 3-4 years. Associations of resulting clusters with potential early-life risk factors and 10-year asthma outcomes were further assessed.
    Results: Five clusters were identified in both cohorts: (1) infantile-onset-transient-non-atopic-wheeze, (2) infantile-onset-persistent-non-atopic-wheeze, (3) infantile-onset-atopic-wheeze, (4) early-childhood-onset-non-atopic-wheeze, and (5) early-childhood-onset-atopic-wheeze. Two atopic wheezing clusters (3 and 5) were associated with greatest early-life wheeze frequency, highest wheeze persistence, and asthma prevalence at 10 years. Cluster 1 was commonest but had lowest early-life wheeze frequency and asthma prevalence at 10 years. Cluster 2, characterized by limited atopy but recurrent infantile respiratory infections and ongoing early-life wheezing, had high 10-year asthma prevalence only in IOWBC.
    Conclusions: Early-life wheeze comprises several disease clusters (two more severe and three mild-moderate) with differing relationships to later childhood asthma, which can be replicated over time supporting their potential validity and clinical utility.
    Mesh-Begriff(e) Humans ; Infant ; Child ; Birth Cohort ; Respiratory Sounds/etiology ; Hypersensitivity, Immediate/epidemiology ; Asthma/diagnosis ; Asthma/epidemiology ; Asthma/complications ; Risk Factors ; Prognosis ; Phenotype
    Sprache Englisch
    Erscheinungsdatum 2023-07-26
    Erscheinungsland England
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 1057059-7
    ISSN 1399-3038 ; 0905-6157 ; 0906-5784
    ISSN (online) 1399-3038
    ISSN 0905-6157 ; 0906-5784
    DOI 10.1111/pai.13999
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: Prediction of adult asthma risk in early childhood using novel adult asthma predictive risk scores

    Farhan, Abdal J. / Kothalawala, Dilini M. / Kurukulaaratchy, Ramesh J. / Granell, Raquel / Simpson, Angela / Murray, Clare / Custovic, Adnan / Roberts, Graham / Zhang, Hongmei / Arshad, S. Hasan

    Allergy. 2023 Nov., v. 78, no. 11, p. 2969-2979

    2023  , Seite(n) 2969–2979

    Abstract: BACKGROUND: Numerous risk scores have been developed to predict childhood asthma. However, they may not predict asthma beyond childhood. We aim to create childhood risk scores that predict development and persistence of asthma up to young adult life. ... ...

    Abstract BACKGROUND: Numerous risk scores have been developed to predict childhood asthma. However, they may not predict asthma beyond childhood. We aim to create childhood risk scores that predict development and persistence of asthma up to young adult life. METHODS: The Isle of Wight Birth Cohort (n = 1456) was prospectively assessed up to 26 years of age. Asthma predictive scores were developed based on factors during the first 4 years, using logistic regression and tested for sensitivity, specificity and area under the curve (AUC) for prediction of asthma at (i) 18 and (ii) 26 years, and persistent asthma (PA) (iii) at 10 and 18 years, and (iv) at 10, 18 and 26 years. Models were internally and externally validated. RESULTS: Four models were generated for prediction of each asthma outcome. ASthma PredIctive Risk scorE (ASPIRE)‐1: a 2‐factor model (recurrent wheeze [RW] and positive skin prick test [+SPT] at 4 years) for asthma at 18 years (sensitivity: 0.49, specificity: 0.80, AUC: 0.65). ASPIRE‐2: a 3‐factor model (RW, +SPT and maternal rhinitis) for asthma at 26 years (sensitivity: 0.60, specificity: 0.79, AUC: 0.73). ASPIRE‐3: a 3‐factor model (RW, +SPT and eczema at 4 years) for PA‐18 (sensitivity: 0.63, specificity: 0.87, AUC: 0.77). ASPIRE‐4: a 3‐factor model (RW, +SPT at 4 years and recurrent chest infection at 2 years) for PA‐26 (sensitivity: 0.68, specificity: 0.87, AUC: 0.80). ASPIRE‐1 and ASPIRE‐3 scores were replicated externally. Further assessments indicated that ASPIRE‐1 can be used in place of ASPIRE‐2‐4 with same predictive accuracy. CONCLUSION: ASPIRE predicts persistent asthma up to young adult life.
    Schlagwörter asthma ; chest ; childhood ; eczema ; models ; prediction ; regression analysis ; rhinitis ; risk ; skin prick tests ; young adults
    Sprache Englisch
    Erscheinungsverlauf 2023-11
    Umfang p. 2969-2979
    Erscheinungsort John Wiley & Sons, Ltd
    Dokumenttyp Artikel ; Online
    Anmerkung JOURNAL ARTICLE
    ZDB-ID 391933-x
    ISSN 1398-9995 ; 0105-4538
    ISSN (online) 1398-9995
    ISSN 0105-4538
    DOI 10.1111/all.15876
    Datenquelle NAL Katalog (AGRICOLA)

    Zusatzmaterialien

    Kategorien

  8. Artikel ; Online: Response to correspondence: Prediction of adult asthma risk in early childhood using novel adult asthma predictive risk scores.

    Farhan, Abdal J / Kothalawala, Dilini M / Kurukulaaratchy, Ramesh J / Granell, Raquel / Simpson, Angela / Murray, Clare / Custovic, Adnan / Roberts, Graham / Zhang, Hongmei / Arshad, S Hasan

    Allergy

    2024  

    Sprache Englisch
    Erscheinungsdatum 2024-02-13
    Erscheinungsland Denmark
    Dokumenttyp Letter
    ZDB-ID 391933-x
    ISSN 1398-9995 ; 0105-4538
    ISSN (online) 1398-9995
    ISSN 0105-4538
    DOI 10.1111/all.16059
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Online: Preserved antibody responses to COVID-19 vaccination and lower odds of developing COVID-19 in adults with severe asthma.

    Rupani, Hitasha / Edwards, Diane / Chaudhuri, Rekha / Smith, Steven / Jackson, David J / Hearn, Andrew / Richards, Jennifer / Moyses, Helen / Kurukulaaratchy, Ramesh J / Haitchi, Hans Michael / Edwards, Michael R / Johnston, Sebastian L / Djukanovic, Ratko

    The journal of allergy and clinical immunology. In practice

    2024  

    Sprache Englisch
    Erscheinungsdatum 2024-05-23
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2843237-X
    ISSN 2213-2201 ; 2213-2198
    ISSN (online) 2213-2201
    ISSN 2213-2198
    DOI 10.1016/j.jaip.2024.05.026
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  10. Artikel ; Online: Blood cytokine profiles - Potential biomarkers for asthma persistence into adulthood?

    Fong, Wei Chern Gavin / Kadalayil, Latha / Lau, Laurie / Kurukulaaratchy, Ramesh J / Arshad, Syed Hasan

    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology

    2021  Band 33, Heft 1, Seite(n) e13673

    Mesh-Begriff(e) Adult ; Asthma/diagnosis ; Biomarkers ; Cytokines ; Humans ; Hypersensitivity
    Chemische Substanzen Biomarkers ; Cytokines
    Sprache Englisch
    Erscheinungsdatum 2021-10-11
    Erscheinungsland England
    Dokumenttyp Letter ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1057059-7
    ISSN 1399-3038 ; 0905-6157 ; 0906-5784
    ISSN (online) 1399-3038
    ISSN 0905-6157 ; 0906-5784
    DOI 10.1111/pai.13673
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang